Vibrational Spectroscopy for the Triage of Traumatic Brain Injury Computed Tomography Priority and Hospital Admissions

Ashton G. Theakstone, Paul M. Brennan, Katherine M. Ashton, Endre Czeiter, Michael D. Jenkinson, Khaja Syed, Matthew J. Reed, Matthew J. Baker, Cecilia Åkerlund, Krisztina Amrein, Nada Anđelić, Lasse Andreassen, Audny Anke, Anna Degli Antoni, Gérard Audibert, Philippe Azouvi, Maria Luisa Azzolini, Ronald Bartels, Pál Barzó, Romuald Beauvais, Ronny Beer, Bo‐Michael Bellander, Antonio Belli, Habib Benali, Maurizio Berardino, Luigi Beretta, Morten Blaabjerg, Peter Bragge, Alexandra Bražinová, Vibeke Brinck, Joanne Brooker, Caroline Brorsson, András Büki, Monika Bullinger, Manuel Cabeleira, Alessio Caccioppola, Emiliana Calappi, Maria Rosa Calvi, Peter Cameron, Guillermo Carbayo Lozano, Marco Carbonara, Simona Cavallo, Giorgio Chevallard, Arturo Chieregato, Giuseppe Citerio, Hans Clusmann, Mark Coburn, Jonathan Coles, D. James Cooper, Marta Correia, Amra Čović, Nicola Curry, Marek Czosnyka, Claire Dahyot‐Fizelier, Paul Dark, Helen Dawes, Véronique De Keyser, Vincent Degos, Françesco Della Corte, Hugo den Boogert, Bart Depreitere, Đula Đilvesi, Abhishek Dixit, Emma Donoghue, Jens P. Dreier, Guy‐Loup Dulière, Ari Ercole, Patrick Esser, Erzsébet Ezer, Martin Fabricius, Valery L. Feigin, Kelly Foks, Shirin Frisvold, Alex Furmanov, Pablo Gagliardo, Damien Galanaud, Dashiell Gantner, Guoyi Gao, Pradeep George, Alexandre Ghuysen, Lelde Giga, Ben Glocker, Jagoš Golubović, Pedro A. Gómez, Johannes Gratz, Benjamin Gravesteijn, Francesca Grossi, Russell L. Gruen, Deepak Gupta, Juanita A. Haagsma, Iain Haitsma, Raimund Helbok, Eirik Helseth, Lindsay Horton, Jilske Huijben, Peter J. Hutchinson, Bram Jacobs, Stefan Jankowski, Mike Jarrett, Jiyao JiangJournal of Neurotrauma 2022 · DOI

TL;DR

This paper introduces a novel blood-based liquid biopsy using ATR-FTIR spectroscopy and machine learning to triage patients with suspected traumatic brain injury (TBI). The method shows high accuracy in distinguishing TBI patients from healthy controls and holds promise for reducing unnecessary CT scans, thereby saving costs and patient radiation exposure.

What Problem Does This Paper Address?

Traumatic brain injury (TBI) is a significant global health concern, with millions of new cases annually. Current clinical practice relies heavily on Computed Tomography (CT) scans to assess TBI severity and guide treatment. However, a large majority (93%) of CT scans in TBI patients reveal no abnormalities, leading to substantial healthcare costs and unnecessary radiation exposure for patients, particularly those with mild TBI. There's a critical need for a more efficient and less invasive triage tool to identify patients who truly require CT imaging, especially for mild TBI cases where outcomes like hospital admission are the primary concern.

Methods

The researchers developed a diagnostic approach utilizing Attenuated Total Reflectance-Fourier Transform Infrared (ATR-FTIR) spectroscopy on blood serum. This technique probes the vibrational modes of molecules within the serum, providing a complex spectral fingerprint that reflects the overall biochemical composition. Instead of targeting specific biomarkers, this method captures a broad "phenotypic" profile.

This spectral data was then fed into machine learning algorithms for classification. Specifically, they employed:

  • Principal Component Analysis (PCA) for exploratory analysis to visualize and understand the separation between different patient groups.
  • Partial Least Squares-Discriminant Analysis (PLS-DA), Random Forest (RF), and Support Vector Machine (SVM) for classification tasks.

The data pre-processing involved techniques like min-max normalization, binning, and extended multiplicative signal correction (EMSC). To handle class imbalance (more non-injury controls than injury patients), they used the Synthetic Minority Oversampling Technique (SMOTE). The models were trained and validated using a split of 70% training and 30% testing data, with five-fold cross-validation.

Datasets

The study utilized serum samples from two groups:

  • CENTER-TBI cohort: 298 patients with TBI (all severities) collected within 24 hours of injury from 65 sites across Europe and Israel. Of these, 222 had GCS scores and six-month GOSE values.
  • Asymptomatic controls: 87 individuals whose serum samples were obtained from Royal Preston Hospital.

The dataset was not a newly introduced benchmark but rather a collection of samples from a large, existing prospective observational study (CENTER-TBI).

Key Insights and Ideas

  • Serum as a Window into TBI: The study demonstrates that the complex biochemical profile of blood serum, as captured by ATR-FTIR, contains sufficient information to distinguish between individuals with and without TBI. This suggests that systemic responses to head injury are reflected in the blood.
  • Amide I and Amide II Regions are Key: The PCA analysis revealed that the spectral variations responsible for differentiating TBI patients from controls primarily lie within the Amide I and Amide II regions of the infrared spectrum. These regions are known to be associated with protein and peptide structures, hinting at protein-level changes in response to injury.
  • Machine Learning for Triage: The application of machine learning, particularly PLS-DA, proved highly effective in translating complex spectral data into actionable diagnostic classifications, showcasing the power of these algorithms in interpreting high-dimensional biological data.
  • Age and Gender Independence: A crucial finding is that the developed classification models are not significantly influenced by patient age or gender, making the test broadly applicable across diverse patient populations.

Key Results

  • TBI vs. Non-Injury Controls (All Severities): The PLS-DA model achieved excellent performance, with a sensitivity of 96.0%, specificity of 98.1%, and balanced accuracy of 97.1%.
  • Mild TBI vs. Non-Injury Controls: The PLS-DA model showed even higher performance in this specific subgroup, with sensitivity of 96.4%, specificity of 98.0%, and balanced accuracy of 97.2%. The Area Under the Curve (AUC) for the ROC analysis was an impressive 0.998.
  • Mild TBI with CT Abnormality vs. Mild TBI without CT Abnormality: This more challenging classification yielded a sensitivity of 80.2%. This means the test can identify CT abnormalities in approximately four out of every five mild TBI patients who have them. The specificity in this subgroup was lower (33.2% for PLS-DA).

Limitations and Future Work

  • Specificity in Mild TBI Subgroup: The study acknowledges that stratifying mild TBI patients with and without CT abnormalities was less accurate, particularly in terms of specificity. While the high sensitivity is promising for identifying those with abnormalities, the lower specificity means a significant portion of patients flagged as having an abnormality might not actually have one on CT.
  • Definition of CT Abnormality: The study notes that their CT abnormality classification was based on the number of abnormalities, which might oversimplify the severity of individual findings.
  • Future Work:
    • Combination with Clinical Data: The authors suggest exploring the enhancement of test accuracy by combining spectral data with existing clinical features (like GCS scores and pupil reactivity) and patient demographics.
  • Refinement of Machine Learning Algorithms: Further optimization of the machine learning models could improve performance.
  • Validation in Broader Populations: Future prospective studies should validate the test in patients with other cranial pathologies (e.g., stroke, brain tumors) and assess its role in prognostication and predicting long-term complications.
  • Clinical Integration: The test is envisioned as an adjunct to clinical assessment, not a replacement, and its impact on clinical decision-making and patient pathways needs further evaluation.

Summary updated

Abstract

Computed tomography (CT) brain imaging is routinely used to support clinical decision-making in patients with traumatic brain injury (TBI). Only 7% of scans, however, demonstrate evidence of TBI. The other 93% of scans contribute a significant cost to the healthcare system and a radiation risk to patients. There may be better strategies to identify which patients, particularly those with mild TBI, are at risk of deterioration and require hospital admission. We introduce a blood serum liquid biopsy that utilizes attenuated total reflectance (ATR)-Fourier transform infrared (FTIR) spectroscopy with machine learning algorithms as a decision-making tool to identify which patients with mild TBI will most likely present with a positive CT scan. Serum samples were obtained from patients (<i>n</i> = 298) patients who had acquired a TBI and were enrolled in CENTER-TBI and from asymptomatic control patients (<i>n</i> = 87). Injury patients (all severities) were stratified against non-injury controls. The cohort with mild TBI was further examined by stratifying those who had at least one CT abnormality against those who had no CT abnormalities. The test performed exceptionally well in classifications of patients with mild injury versus non-injury controls (sensitivity = 96.4% and specificity = 98.0%) and also provided a sensitivity of 80.2% when stratifying mild patients with at least one CT abnormality against those without. The results provided illustrate the test ability to identify four of every five CT abnormalities and show great promise to be introduced as a triage tool for CT priority in patients with mild TBI.
BibTeX
@article{theakstone2022vibrational,
  author = {Ashton G. Theakstone and Paul M. Brennan and Katherine M. Ashton and Endre Czeiter and Michael D. Jenkinson and Khaja Syed and Matthew J. Reed and Matthew J. Baker and Cecilia Åkerlund and Krisztina Amrein and Nada Anđelić and Lasse Andreassen and Audny Anke and Anna Degli Antoni and Gérard Audibert and Philippe Azouvi and Maria Luisa Azzolini and Ronald Bartels and Pál Barzó and Romuald Beauvais and Ronny Beer and Bo‐Michael Bellander and Antonio Belli and Habib Benali and Maurizio Berardino and Luigi Beretta and Morten Blaabjerg and Peter Bragge and Alexandra Bražinová and Vibeke Brinck and Joanne Brooker and Caroline Brorsson and András Büki and Monika Bullinger and Manuel Cabeleira and Alessio Caccioppola and Emiliana Calappi and Maria Rosa Calvi and Peter Cameron and Guillermo Carbayo Lozano and Marco Carbonara and Simona Cavallo and Giorgio Chevallard and Arturo Chieregato and Giuseppe Citerio and Hans Clusmann and Mark Coburn and Jonathan Coles and D. James Cooper and Marta Correia and Amra Čović and Nicola Curry and Marek Czosnyka and Claire Dahyot‐Fizelier and Paul Dark and Helen Dawes and Véronique De Keyser and Vincent Degos and Françesco Della Corte and Hugo den Boogert and Bart Depreitere and Đula Đilvesi and Abhishek Dixit and Emma Donoghue and Jens P. Dreier and Guy‐Loup Dulière and Ari Ercole and Patrick Esser and Erzsébet Ezer and Martin Fabricius and Valery L. Feigin and Kelly Foks and Shirin Frisvold and Alex Furmanov and Pablo Gagliardo and Damien Galanaud and Dashiell Gantner and Guoyi Gao and Pradeep George and Alexandre Ghuysen and Lelde Giga and Ben Glocker and Jagoš Golubović and Pedro A. Gómez and Johannes Gratz and Benjamin Gravesteijn and Francesca Grossi and Russell L. Gruen and Deepak Gupta and Juanita A. Haagsma and Iain Haitsma and Raimund Helbok and Eirik Helseth and Lindsay Horton and Jilske Huijben and Peter J. Hutchinson and Bram Jacobs and Stefan Jankowski and Mike Jarrett and Jiyao Jiang},
  title = {{Vibrational Spectroscopy for the Triage of Traumatic Brain Injury Computed Tomography Priority and Hospital Admissions}},
  journal = {Journal of Neurotrauma},
  year = {2022},
  doi = {10.1089/neu.2021.0410},
}
Figure